Statins potentiate the IFN-γ-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1733, Issue 2-3, 2005, Pages 157-171

  Menschikowski, Mario ^a   Hagelgans, Albert ^a   Heyne, Ben ^a   Hempel, Ute ^a   Neumeister, Volker ^a   Goez, Peter ^a   Jaross, Werner ^a   Siegert, Gabriele ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

HASMC; HepG2 cells; HMG CoA reductase inhibitor; Inflammation; Secretory phospholipase A2; Statin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ATORVASTATIN; CLOSTRIDIUM DIFFICILE TOXIN B; COMPACTIN; FARNESYL DIPHOSPHATE; GAMMA INTERFERON; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RHO FACTOR;

AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UPREGULATION;

CLOSTRIDIUM DIFFICILE; JANUS;

EID: 18044364209     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2005.01.001     Document Type: Article

References (70)

1. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
2. C.J. Vaughan, M.B. Murphy, and B.M. Buckley Statins do more than just lower cholesterol Lancet 348 1996 1079 1082
3. J. Auer, R. Berent, T. Weber, and B. Eber Clinical significance of pleiotropic effects of statins: lipid reduction and beyond Curr. Med. Chem. 9 2002 1831 1850
4. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
5. P. Negre-Aminou, A.K. van Vliet, M. van Erck, G.C. van Thiel, R.E. van Leeuwen, and L.H. Cohen Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types Biochim. Biophys. Acta 1345 1997 259 268
6. U. Laufs, D. Marra, K. Node, and J.K. Liao 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1) J. Biol. Chem. 274 1999 21926 21931
7. C. Bustos, M.A. Hernandez-Presa, M. Ortego, J. Tunon, L. Ortega, F. Perez, C. Diaz, G. Hernandez, and J. Egido HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis J. Am. Coll. Cardiol. 32 1998 2057 2064
8. S. Takeuchi, S. Kawashima, Y. Rikitake, T. Ueyama, N. Inoue, K. Hirata, and M. Yokoyama Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC Biochem. Biophys. Res. Commun. 269 2000 97 102
9. F. Degraeve, M. Bolla, S. Blaie, C. Creminon, I. Quere, P. Boquet, S. Levy-Toledano, J. Bertoglio, and A. Habib Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins J. Biol. Chem. 276 2001 46849 46855
10. Y. Hattori, N. Nakanishi, and K. Kasai Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells Cardiovasc. Res. 54 2002 649 658
11. L.M. Rasmussen, P.R. Hansen, M.T. Nabipour, P. Olesen, M.T. Kristiansen, and T. Ledet Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells Biochem. J. 360 2001 363 370
12. 2 J. Biol. Chem. 264 1989 5768 5775
13. 2 Crit. Rev. Immunol. 17 1997 225 283
14. 2 protein and mRNA in rat tissues J. Histochem. Cytochem. 48 2000 1469 1478
15. 2 gene expression in human hepatoma cells by mediators of the acute-phase response J. Biol. Chem. 266 1991 2647 2651
16. 2 J. Lipid Mediators Cell Signal. 12 1995 119 130
17. 2 levels: correlation with hemodynamic and pulmonary changes in gram-negative septic shock J. Lab. Clin. Med. 104 1984 873 881
18. 2 expression and pathogenesis of the sepsis syndrome Circ. Shock 39 1993 160 167
19. 2 in human acute pancreatitis Gastroenterology 97 1989 1521 1526
20. 2 levels correlate with disease activity in rheumatoid arthritis J. Rheumatol. 15 1988 1351 1355
21. 2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis Klin. Wochenschr. 67 1989 217 221
22. 2 in patients with multiple injuries J. Trauma 30 1990 1285 1290
23. 2. Basic and clinical aspects in inflammatory diseases 1997 Karger Basel 200 204
24. 2 in serum is an acute phase reactant Res. Commun. Chem. Pathol. Pharmacol. 75 1992 109 115
25. 2. Basic and clinical aspects in inflammatory diseases 1997 Karger Basel 104 107
26. 2 enzymes: classification and characterization Biochim. Biophys. Acta 1488 2000 1 19
27. 2 enzymes Prostaglandins Other Lipid Mediat. 68-69 2002 3 58
28. 2 to Escherichia coli infection Infect. Immun. 68 2000 87 92
29. 2 in serum of patients with bacterial infections J. Infect. Dis. 185 2002 1767 1772
30. 2 J. Biol. Chem. 277 2002 5849 5857
31. R.J. Gerson, J.S. MacDonald, A.W. Alberts, D.J. Kornbrust, J.A. Majka, R.J. Stubbs, and D.L. Bokelman Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors Am. J. Med. 87 1989 28S 38S
32. F. Martinez, S. Eschegoyen, R. Briones, and A. Cuellar Cholesterol increase in mitochondria: a new method of cholesterol incorporation J. Lipid Res. 29 1988 1005 1011
33. 2 Adv. Exp. Med. Biol. 279 1990 173 184
34. L. Ercolani, B. Florence, M. Denaro, and M. Alexander Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene J. Biol. Chem. 263 1988 15335 15341
35. P. Renard, I. Ernest, A. Houbion, M. Art, H. Le Calvez, M. Raes, and J. Remacle Development of a sensitive multi-well colorimetric assay for active NF-κB Nucleic Acids Res. 29 2001 E21
36. 2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines J. Biol. Chem. 275 2000 22895 22904
37. 2-a mediator between proximal and distal effectors of inflammation Immunol. Today 12 1991 143 146
38. C. Guijarro, L.M. Blanco-Colio, M. Ortego, C. Alonso, A. Ortiz, J.J. Plaza, C. Diaz, G. Hernandez, and J. Egido 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ. Res. 83 1998 490 500
39. V. Quesney-Huneeus, M.H. Wiley, and M.D. Siperstein Essential role for mevalonate synthesis in DNA replication Proc. Natl. Acad. Sci. U. S. A. 76 1979 5056 5060
40. 2 gene in vascular smooth muscle cells by a nuclear factor κB and peroxisome proliferators-activated receptor-mediated process J. Biol. Chem. 274 1999 23085 23093
41. J. Blanchette, M. Jaramillo, and M. Olivier Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation Immunology 108 2003 513 522
42. 2 gene transcription involves C/EBP-β and -δ in vascular smooth muscle cells Arterioscler. Thromb. Vasc. Biol. 20 2000 2559 2565
43. 2 Biochim. Biophys. Acta 1488 2000 149 158
44. I. Just, J. Selzer, M. Wilm, C. von Eichel-Streiber, M. Mann, and K. Aktories Glucosylation of Rho proteins by Clostridium difficile toxin B Nature 375 1995 500 503
45. E. Sahai, T. Ishizaki, S. Narumiya, and R. Treisman Transformation mediated by RhoA requires activity of ROCK kinases Curr. Biol. 9 1999 136 145
46. C. Petry, G. Fritz, J. Pfeilschifter, and A. Huwiler Inhibition of Rho modulates cytokine-induced prostaglandin E2 formation in renal mesangial cells Biochim. Biophys. Acta 1636 2004 108 118
47. 2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells FEBS Lett. 261 1990 171 174
48. 2 in rat cultured astrocytes. Two distinct pathways of the gene expression J. Biol. Chem. 266 1991 9956 9960
49. 2 from human articular chondrocytes J. Rheumatol. 22 1995 2114 2119
50. 2 mRNA and activity levels in interleukin 1β- and forskolin-stimulated mesangial cells Biochem. J. 315 1996 435 441
51. P. Lang, F. Gesbert, M. Delespine-Carmagnat, R. Stancou, M. Pouchelet, and J. Bertoglio Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes EMBO J. 15 1996 510 519
52. J.M. Dong, T. Leung, E. Manser, and L. Lim cAMP-induced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROKα J. Biol. Chem. 273 1998 22554 22562
53. Z.J. Tian, and W. An ERK 1/2 contributes negative regulation to STAT3 activity in HSS-transfected HepG2 cells Cell Res. 14 2004 141 147
54. J. Darnell Jr., I. Kerr, and G. Stark Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1994 1415 1421
55. T.K. Held, X. Weihua, L. Yuan, D.V. Kalvakolanu, and A.S. Cross Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor-α and interleukin-1 Infect. Immun. 67 1999 206 212
56. M. Hiroi, and Y. Ohmori The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-κB for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-γ gene J. Biol. Chem. 278 2003 651 660
57. 2 in rat renal mesangial cells Br. J. Pharmacol. 121 1997 787 793
58. 2 in rat mesangial cells J. Pharmacol. Exp. Ther. 292 2000 271 279
59. 2 gene by cAMP and interleukin-1β in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-κB and Ets transcription factors Biochem. J. 368 2002 415 424
60. 2 promoter and binds several non-zinc finger proteins Eur. J. Biochem. 258 1998 113 122
61. M. Menschikowski, M. Kasper, P. Lattke, A. Schiering, S. Schiefer, H. Stockinger, and W. Jaross Secretory group II phospholipase A2 in human atherosclerotic plaques Atherosclerosis 118 1995 173 181
62. B. Ivandic, L.W. Castellani, X.P. Wang, J.H. Qiao, M. Mehrabian, M. Navab, A.M. Fogelman, D.S. Grass, M.E. Swanson, M.C. de Beer, F. de Beer, and A.J. Lusis Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2 Arterioscler. Thromb. Vasc. Biol. 19 1999 1284 1290
63. 2 in vascular disease Circ. Res. 89 2001 298 304
64. 2 group IIA on lipoproteins and in atherogenesis Eur. J. Clin. Invest. 32 2002 383 393
65. 2s Adv. Immunol. 77 2001 163 194
66. 2 isoforms in the checkpoint control of acute inflammation FASEB J. 18 2004 489 498
67. 2 generates anti-apoptotic survival signals in kidney fibroblasts J. Biol. Chem. 274 1999 27726 27733
68. A.P. Liappis, V.L. Kan, C.G. Rochester, and G.L. Simon The effect of statins on mortality in patients with bacteremia Clin. Infect. Dis. 33 2001 1352 1357
69. R.H. Stern, B.B. Yang, N.J. Hounslow, M. MacMahon, R.B. Abel, and S.C. Olson Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor J. Clin. Pharmacol. 40 2000 616 623
70. H. Lennernas Clinical pharmacokinetics of atorvastatin Clin. Pharmacokinet. 42 2003 1141 1160